ALS Research Pipeline Explained: Current Treatments, Clinical Trials, and the Future of ALS Therapy

If you’re wondering about the ALS research pipeline, here’s where things stand today for ALS, MND, ALS disease—also known as Amyotrophic lateral sclerosis, Motor Neuron disease, or Lou Gehrig’s disease. The ALS research pipeline includes approved treatments, drugs in clinical trials, and emerging approaches aimed at slowing or stopping disease progression. Right now, standard ALS treatment often includes riluzole and edaravone. For a small group of people with a specific genetic mutation (SOD1), tofersen is available. These therapies do not represent an ALS cure, but they mark important steps forward. Many people searching “what is ALS” also ask: Is ALS genetic? and Are there ALS clinical trials near me? The answer is that some forms, like Familial ALS, are genetic, and research studies are expanding rapidly. One major shift in the ALS research pipeline is the rise of platform trials, which test multiple therapies at once. This speeds up progress and helps researchers learn faster which approaches truly affect ALS symptoms and ALS prognosis. Current research focuses on several areas: gene-targeted therapies, RNA and protein dysfunction (like TDP-43), neuroinflammation, mitochondrial support, and devices that better track ALS stages. Scientists are also improving biomarkers to measure disease activity earlier, which could change how ALS diagnosis and ALS treatment evolve. What’s holding progress back? ALS disease is highly variable. Timing matters, and many trials begin after significant nerve loss. Still, momentum is building. This video is for people newly diagnosed, care partners, members of the ALS community, and anyone asking, “How long do you live with ALS?” or “Is there progress toward an ALS cure?” It offers a clear, accessible overview of where research stands—and where it’s headed.